53 completed, 7 active not recruiting, 7 terminated, 2 recruiting. 30 Phase 2, 22 Phase 1, 18 Phase 3, 3 Phase 4.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Recruiting | Bavarian Nordic | 6144 | 2026-05-26 | 2026-06-29 |
| Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells Jynneos, MVA-BN (Quail) - Monkeypox (Mpox) | Phase 2 | Active not recruiting | Bavarian Nordic | 970 | 2025-10-27 | 2026-04-08 |
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP) - Neonate, Maternal Transmission | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 359 | 2025-06-23 | 2026-01-30 |
| A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Active not recruiting | Bavarian Nordic | 720 | 2025-06-05 | 2026-09-30 |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN half-dose regimen - Mpox (Monkeypox), Vaccination | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 344 | 2025-05-29 | 2026-04-29 |
| Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana IXCHIQ, VIMKUNYA - Chikungunya Virus Infection | Phase 4 | Recruiting | Centre Hospitalier Universitaire de la Réunion | 1505 | 2025-04-18 | 2026-09-28 |
| A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine MVA-BN-WEV, Placebo - Encephalitis | Phase 2 | Active not recruiting | Bavarian Nordic | 411 | 2025-03-10 | 2025-10-01 |
| Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections MVA-BN - Monkeypox (Mpox) | Phase 2 | Active not recruiting | Bavarian Nordic | 460 | 2024-10-21 | 2025-11-24 |
| Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination CHIKV VLP vaccine booster, Placebo booster - Chikungunya Virus Infection | Phase 3 | Active not recruiting | Bavarian Nordic | 715 | 2023-08-30 | 2026-08-07 |
| ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 ABNCoV2, Comirnaty - COVID-19 Disease | Phase 3 | Completed | Bavarian Nordic | 4205 | 2022-08-30 | 2025-02-24 |
| Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 413 | 2022-05-12 | 2024-12-13 |
| MVA-BN-RSV Vaccine Trial MVA-BN-RSV vaccine, Tris Buffered Saline (TBS) - Respiratory Syncytial Virus Infections | Phase 3 | Terminated | Bavarian Nordic | 20419 | 2022-04-19 | 2024-10-31 |
| A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine CHIKV VLP, adjuvanted - Chikungunya Virus | Phase 2 | Completed | Bavarian Nordic | 25 | 2021-10-11 | 2023-07-03 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 3258 | 2021-09-29 | 2024-08-30 |
| ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects ABNCoV2 100ug, ABNCoV2 50ug - COVID-19 Disease | Phase 2 | Completed | Bavarian Nordic | 197 | 2021-08-19 | 2024-09-27 |
| Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults MVA-mBN294B, Placebo - RSV Infection | Phase 2 | Completed | Bavarian Nordic | 73 | 2021-02-22 | 2023-07-21 |
| TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer TAEK-VAC-HerBy - Chordoma, HER2-positive Breast Cancer | Phase 1 | Completed | Bavarian Nordic | 37 | 2020-08-10 | 2025-03-03 |
| A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer MVA-BN-Brachyury - Solid Metastatic Tumor | Phase 1 | Completed | Bavarian Nordic | 13 | 2020-01-08 | 2021-07-14 |
| Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Chikungunya - Chikungunya | Phase 2 | Completed | Bavarian Nordic | 60 | 2019-11-20 | 2024-10-16 |
| Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer MVA-BN-Brachyury - Prostate Adenocarcinoma | Phase 2 | Withdrawn | University of Utah | 2019-11-20 | 2021-09-22 |
Showing 20 of 71. Sign in to see all of them.
Smallpox (13) · Chikungunya Fever (8) · HIV Infections (7) · Mpox, Monkeypox (6) · Cholera (5) · Respiratory Syncytial Virus Infections (5) · Prostatic Neoplasms (4) · Neoplasm Metastasis (3) · Acquired Immunodeficiency Syndrome (2) · Breast Neoplasms (2) · Chordoma (2) · Colorectal Neoplasms (2) · Dermatitis, Atopic (2) · Encephalomyelitis, Equine (2) · Carcinoma, Non-Small-Cell Lung (1)
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (19) · Nivolumab (3) · PROSTVAC (3) · ABNCoV2 vaccine (2) · Ipilimumab (2) · atezolizumab (2) · ACAM2000 (1) · BNT162 Vaccine (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Capecitabine (1) · Cholera Vaccines (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Leukapheresis (1) · MVA-BN-PRO vaccine (1)
United States (50) · Germany (11) · Democratic Republic of the Congo (4) · Puerto Rico (4) · United Kingdom (4) · Belgium (3) · Australia (2) · Denmark (2) · France (2) · Philippines (2) · Uganda (2) · Burkina Faso (1) · Canada (1) · Estonia (1) · French Guiana (1)
James McCarty, MD (5) · Olga Bandman (3) · Patrick Ajiboye, MD (3) · Carlos Fierro, MD (2) · Edgar T Overton, MD (2) · Richard N Greenberg, M.D. (2) · Richard N Greenberg, MD (2) · Andreas Schroedter, M.D. (1) · Bernard Hoet, MD (1) · Carlos A. Fierro, MD (1) · Casey Johnson, DO (1) · Cesar Pico-Navarro, MD (1) · Christine Grigat, MD (1) · Christine Mhorag Hay (1)
PMID 34266694, PMID 35709798, PMID 36263798, PMID 36408618, PMID 42372625, PMID 19944151, PMID 20100959, PMID 23225902, PMID 23349878, PMID 24173028, PMID 25149431, PMID 25879867, PMID 26380340, PMID 26439129, PMID 27001804, PMID 27327616, PMID 27357167, PMID 27646950, PMID 28566334, PMID 29317118, PMID 29624592, PMID 29652929, PMID 29655627, PMID 30445121, PMID 30772070, PMID 30817251, PMID 31722150, PMID 31743334, PMID 31769402, PMID 31876334, PMID 32057574, PMID 32726422, PMID 34479925, PMID 36054490, PMID 36460535, PMID 37079393, PMID 38400193, PMID 38494412, PMID 39004524, PMID 39461302, PMID 39954701, PMID 40158524, PMID 40158526, PMID 41819114, PMID 41819117, PMID 42521300
2015 (1), 2018 (1), 2025 (1)